ERBB2 and breast carcinoma: These findings indicate that the effect of UBE2C overexpression on the survival of patients with early HR+/HER2– breast cancer may be estrogen related, and UBE2C expression can predict the risk of distant recurrence among patients with early HR+/HER2– breast cancer.